^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report

Published date:
02/03/2023
Excerpt:
...we report a patient with advanced lung adenocarcinoma harboring an EGFR exon 20 insertion mutation (NM_005228: exon 20: c.2316_2321dup: p.773_774dup). After experiencing platinum-based chemotherapy, this patient received a combination of furmonertinib and anlotinib and achieved lasting stable disease (SD).
DOI:
https://doi.org/10.3389/fphar.2023.1053805